Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MedAdvisor Limited ( (AU:MDR) ) has issued an announcement.
MedAdvisor Limited announced board changes following the sale of its ANZ business, reflecting a significant change in the company’s scale. Non-Executive Directors Jim Xenos and Kevin Hutchinson have stepped down, with Hutchinson continuing in an advisory role for the US strategic review. Sean Slattery, the recently appointed CFO, joins the board as an Executive Director, bringing extensive financial expertise and experience in US operations. These changes aim to align the board with the company’s current scale and geographic focus, as MedAdvisor continues to explore strategic options.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
More about MedAdvisor Limited
MedAdvisor Solutions is a leader in pharmacy-driven patient engagement solutions, providing personalized experiences to simplify the patient medication journey. The company leverages THRiV, a cloud-based, AI-enabled platform, to enhance pharmacy workflow and patient engagement. MedAdvisor Solutions collaborates with over 34,000 pharmacies across the US, reaching more than two-thirds of the population.
Average Trading Volume: 955,572
Technical Sentiment Signal: Sell
Current Market Cap: A$34.39M
See more data about MDR stock on TipRanks’ Stock Analysis page.